Ilsung Pharm (003120) — Cash Flow Quality Index
Ilsung Pharm (003120) has a Cash Flow Quality Index of -0.91x as of December 2025. Operating cash flow of ₩-3.10 Billion is below net income of ₩3.41 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Ilsung Pharm (003120) cash conversion ratio to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Ilsung Pharm Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Ilsung Pharm across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Ilsung Pharm total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Ilsung Pharm (2013–2025)
Year-by-year earnings quality comparison for Ilsung Pharm. For live market cap and the full company financial profile, see Ilsung Pharm market cap and net worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 3.33x | ₩3.88 Billion | ₩1.17 Billion | ▲ +1124.3% |
| 2024 | -0.33x | ₩-4.26 Billion | ₩13.09 Billion | ▲ +12.2% |
| 2022 | -0.37x | ₩-38.97 Billion | ₩105.24 Billion | ▼ -176.6% |
| 2020 | 0.48x | ₩1.56 Billion | ₩3.22 Billion | ▼ -26.0% |
| 2019 | 0.65x | ₩4.39 Billion | ₩6.72 Billion | ▼ -87.3% |
| 2018 | 5.12x | ₩15.09 Billion | ₩2.95 Billion | ▲ +32.6% |
| 2017 | 3.86x | ₩10.16 Billion | ₩2.63 Billion | ▲ +137.6% |
| 2016 | -10.28x | ₩-31.01 Billion | ₩3.02 Billion | ▼ -16919.6% |
| 2015 | 0.06x | ₩6.04 Billion | ₩98.85 Billion | ▼ -94.1% |
| 2014 | 1.04x | ₩4.19 Billion | ₩4.03 Billion | ▲ +63.2% |
| 2013 | 0.64x | ₩5.06 Billion | ₩7.96 Billion | — |